Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52‐week, open‐label, phase 3 study (UNCOVER‐J)

Psoriasis, a chronic, immune‐mediated skin disease characterized by red, scaly plaques, affects approximately 0.3% of the population in Japan. The aim of this open‐label study was to evaluate the long‐term efficacy and safety of ixekizumab, a humanized, anti‐interleukin‐17A monoclonal antibody, in J...

Descripción completa

Detalles Bibliográficos
Autores principales: Saeki, Hidehisa, Nakagawa, Hidemi, Nakajo, Ko, Ishii, Taeko, Morisaki, Yoji, Aoki, Takehiro, Cameron, Gregory S., Osuntokun, Olawale O., Akasaka, Toshihide, Asano, Yoshihide, Etoh, Takafumi, Fujita, Yasuyuki, Hashimoto, Takashi, Higashiyama, Mari, Igarashi, Atsuyuki, Ihn, Hironobu, Iwatsuki, Keiji, Kabashima, Kenji, Kawada, Akira, Kawashima, Makoto, Nakamura, Koichiro, Okubo, Yukari, Okuyama, Ryuhei, Ozawa, Akira, Sayama, Koji, Seishima, Mariko, Shiohara, Tetsuo, Takahara, Masakazu, Takahashi, Hidetoshi, Takehara, Kazuhiko, Tanese, Keiji, Tani, Mamori, Umezawa, Yoshinori, Watanabe, Hideaki, Yamanaka, Keiichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412888/
https://www.ncbi.nlm.nih.gov/pubmed/27726163
http://dx.doi.org/10.1111/1346-8138.13622

Ejemplares similares

Ejemplares similares